scholarly journals Does Surveillance Increase Survival? Benefits of Periodic Colonoscopy in Patients with Ulcerative Colitis and Colorectal Cancer

Author(s):  
Michael J. Stewart
2001 ◽  
Vol 120 (5) ◽  
pp. A121-A122
Author(s):  
T EZAKI ◽  
M WATANABE ◽  
S FUNAKOSHI ◽  
M NAGANUMA ◽  
T AZUMA ◽  
...  

Cancer ◽  
1995 ◽  
Vol 75 (8) ◽  
pp. 2045-2050 ◽  
Author(s):  
Guido Biasco ◽  
Giovanni Brandi ◽  
Gian Maria Paganelli ◽  
Francesco Paolo Rossini ◽  
Renato Santucci ◽  
...  

1998 ◽  
Vol 115 (5) ◽  
pp. 1079-1083 ◽  
Author(s):  
K NUAKO ◽  
D AHLQUIST ◽  
D MAHONEY ◽  
D SCHAID ◽  
D SIEMS ◽  
...  

2021 ◽  
Vol 98 (1) ◽  
pp. 110-112
Author(s):  
Mitsuhiro Nakao ◽  
Osamu Ikezaki ◽  
Tomoya Hiratsuka ◽  
Mayumi Ide ◽  
Ryusuke Shimada ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-15 ◽  
Author(s):  
Zhiqi Wang ◽  
Sai Li ◽  
Yu Cao ◽  
Xuefei Tian ◽  
Rong Zeng ◽  
...  

Oxidative stress has long been known as a pathogenic factor of ulcerative colitis (UC) and colitis-associated colorectal cancer (CAC), but the effects of secondary carbonyl lesions receive less emphasis. In inflammatory conditions, reactive oxygen species (ROS), such as superoxide anion free radical (O2∙-), hydrogen peroxide (H2O2), and hydroxyl radical (HO∙), are produced at high levels and accumulated to cause oxidative stress (OS). In oxidative status, accumulated ROS can cause protein dysfunction and DNA damage, leading to gene mutations and cell death. Accumulated ROS could also act as chemical messengers to activate signaling pathways, such as NF-κB and p38 MAPK, to affect cell proliferation, differentiation, and apoptosis. More importantly, electrophilic carbonyl compounds produced by lipid peroxidation may function as secondary pathogenic factors, causing further protein and membrane lesions. This may in turn exaggerate oxidative stress, forming a vicious cycle. Electrophilic carbonyls could also cause DNA mutations and breaks, driving malignant progression of UC. The secondary lesions caused by carbonyl compounds may be exceptionally important in the case of host carbonyl defensive system deficit, such as aldo-keto reductase 1B10 deficiency. This review article updates the current understanding of oxidative stress and carbonyl lesions in the development and progression of UC and CAC.


2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Lin Chen ◽  
Yan Lin ◽  
Zijun Zhang ◽  
Ruisheng Yang ◽  
Xiaosheng Bai ◽  
...  

Abstract Background There is an obvious correlation between ulcerative colitis and colorectal cancer, and the risk of colorectal cancer in patients with ulcerative colitis is increasing. Therefore, the combination therapy of anti-inflammatory and anti-tumor drugs may show promising to inhibit colon cancer. 5-aminosalicylic acid (5-ASA) with anti-inflammatory function is effective for maintaining remission in patients with ulcerative colitis and may also reduce colorectal cancer risk. Histone deacetylase (HDAC) plays an essential role in the progression of colon cancer. Butyric acid (BA) is a kind of HDAC inhibitor and thus shows tumor suppression to colon cancer. However, the volatile and corrosive nature of BA presents challenges in practical application. In addition, its clinical application is limited due to its non-targeting ability and low bioavailability. We aimed to synthesize a novel dual-prodrug of 5-ASA and BA, referred as BBA, to synergistically inhibit colon cancer. Further, based on the fact that folate receptor (FR) is over-expressed in most solid tumors and it has been identified to be a cancer stem cell surface marker in colon cancer, we took folate as the targeting ligand and used carboxymethyl-β-cyclodextrin (CM-β-CD) to carry BBA and thus prepared a novel inclusion complex of BBA/FA-PEG-CM-β-CD. Results It was found that BBA/FA-PEG-CM-β-CD showed significant inhibition in cell proliferation against colon cancer cells SW620. It showed a pro-longed in vivo circulation and mainly accumulated in tumor tissue. More importantly, BBA/FA-PEG-CM-β-CD gave great tumor suppression effect against nude mice bearing SW620 xenografts. Conclusions Therefore, BBA/FA-PEG-CM-β-CD may have clinical potential in colon cancer therapy. Graphical Abstract


Sign in / Sign up

Export Citation Format

Share Document